The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $12.95 in the prior trading day, DENTSPLY Sirona Inc (NASDAQ: XRAY) closed at $12.96, up 0.08%. In other words, the price has increased by $0.08 from its previous closing price. On the day, 2.43 million shares were traded. XRAY stock price reached its highest trading level at $13.12 during the session, while it also had its lowest trading level at $12.825.
Ratios:
Our goal is to gain a better understanding of XRAY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.73. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.69. In the meantime, Its Debt-to-Equity ratio is 1.27 whereas as Long-Term Debt/Eq ratio is at 1.18.
On February 14, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.Wells Fargo initiated its Equal Weight rating on February 14, 2025, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 03 ’25 when LUCIER GREGORY T bought 15,142 shares for $16.51 per share. The transaction valued at 249,994 led to the insider holds 81,971 shares of the business.
Coleman Glenn bought 15,759 shares of XRAY for $311,240 on Jan 27 ’25. On Nov 18 ’24, another insider, LUCIER GREGORY T, who serves as the Director of the company, bought 5,000 shares for $18.37 each. As a result, the insider paid 91,850 and bolstered with 71,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XRAY now has a Market Capitalization of 2585310720 and an Enterprise Value of 4736310784. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.70 while its Price-to-Book (P/B) ratio in mrq is 1.32. Its current Enterprise Value per Revenue stands at 1.29 whereas that against EBITDA is 7.566.
Stock Price History:
The Beta on a monthly basis for XRAY is 1.01, which has changed by -0.48612213 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, XRAY has reached a high of $25.76, while it has fallen to a 52-week low of $12.14. The 50-Day Moving Average of the stock is -6.74%, while the 200-Day Moving Average is calculated to be -18.30%.
Shares Statistics:
The stock has traded on average 3.31M shares per day over the past 3-months and 3487740 shares per day over the last 10 days, according to various share statistics. A total of 199.30M shares are outstanding, with a floating share count of 198.20M. Insiders hold about 0.64% of the company’s shares, while institutions hold 101.78% stake in the company. Shares short for XRAY as of 1757894400 were 8862044 with a Short Ratio of 2.68, compared to 1755216000 on 7878354. Therefore, it implies a Short% of Shares Outstanding of 8862044 and a Short% of Float of 4.96.
Dividends & Splits
In the trailing 12 months, XRAY’s forward annual dividend rate was 0.64, compared to 0.64 this year. Against a Trailing Annual Dividend Yield of 0.04942085. The stock’s 5-year Average Dividend Yield is 1.82.
Earnings Estimates
. The current rating of DENTSPLY Sirona Inc (XRAY) is the result of assessments by 15.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.48, with high estimates of $0.55 and low estimates of $0.44.
Analysts are recommending an EPS of between $1.94 and $1.63 for the fiscal current year, implying an average EPS of $1.87. EPS for the following year is $2.03, with 16.0 analysts recommending between $2.3 and $1.93.
Revenue Estimates
14 analysts predict $901.83M in revenue for. The current quarter. It ranges from a high estimate of $915.8M to a low estimate of $889M. As of. The current estimate, DENTSPLY Sirona Inc’s year-ago sales were $951MFor the next quarter, 14 analysts are estimating revenue of $939.68M. There is a high estimate of $975M for the next quarter, whereas the lowest estimate is $906M.
A total of 17 analysts have provided revenue estimates for XRAY’s current fiscal year. The highest revenue estimate was $3.68B, while the lowest revenue estimate was $3.62B, resulting in an average revenue estimate of $3.65B. In the same quarter a year ago, actual revenue was $3.79BBased on 16 analysts’ estimates, the company’s revenue will be $3.74B in the next fiscal year. The high estimate is $3.84B and the low estimate is $3.64B.
